These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31248841)

  • 1. The association between antidepressant treatment and brain connectivity in two double-blind, placebo-controlled clinical trials: a treatment mechanism study.
    Wang Y; Bernanke J; Peterson BS; McGrath P; Stewart J; Chen Y; Lee S; Wall M; Bastidas V; Hong S; Rutherford BR; Hellerstein DJ; Posner J
    Lancet Psychiatry; 2019 Aug; 6(8):667-674. PubMed ID: 31248841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin-norepinephrine reuptake inhibitor antidepressant effects on regional connectivity of the thalamus in persistent depressive disorder: evidence from two randomized, double-blind, placebo-controlled clinical trials.
    Yang J; Hellerstein DJ; Chen Y; McGrath PJ; Stewart JW; Peterson BS; Wang Z
    Brain Commun; 2022; 4(3):fcac100. PubMed ID: 35592490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term antidepressant administration reduces default mode and task-positive network connectivity in healthy individuals during rest.
    van Wingen GA; Tendolkar I; Urner M; van Marle HJ; Denys D; Verkes RJ; Fernández G
    Neuroimage; 2014 Mar; 88():47-53. PubMed ID: 24269575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.
    Dolder C; Nelson M; Stump A
    Drugs Aging; 2010 Aug; 27(8):625-40. PubMed ID: 20658791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressants normalize the default mode network in patients with dysthymia.
    Posner J; Hellerstein DJ; Gat I; Mechling A; Klahr K; Wang Z; McGrath PJ; Stewart JW; Peterson BS
    JAMA Psychiatry; 2013 Apr; 70(4):373-82. PubMed ID: 23389382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the antidepressant medication duloxetine on brain metabolites in persistent depressive disorder: A randomized, controlled trial.
    Bansal R; Hellerstein DJ; Sawardekar S; O'Neill J; Peterson BS
    PLoS One; 2019; 14(7):e0219679. PubMed ID: 31323045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gray matter reorganization underpinnings of antidepressant treatment of persistent depressive disorder.
    Yang J; Hellerstein DJ; Chen Y; McGrath PJ; Stewart JW; Liu Z; Peterson BS; Wang Z
    Eur Neuropsychopharmacol; 2021 Feb; 43():129-138. PubMed ID: 33402259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder.
    Zhao Q; Fu B; Lyu N; Xu X; Huang G; Tan Y; Xu X; Zhang X; Wang X; Wang Z; Li K; Hu Z; Li H; He H; Li S; Zhao J; He R; Guo H; Li Y; Li L; Yang C; Zou S; Wei B; Wang W; Chen C; Lu Z; He S; Wang Q; Zhao J; Pan X; Pan Z; Li J; Wang G
    J Affect Disord; 2023 May; 329():72-80. PubMed ID: 36813043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?
    Fava M; Mallinckrodt CH; Detke MJ; Watkin JG; Wohlreich MM
    J Clin Psychiatry; 2004 Apr; 65(4):521-30. PubMed ID: 15119915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
    Liebowitz MR; Yeung PP; Entsuah R
    J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine versus other anti-depressive agents for depression.
    Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
    Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
    Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
    Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA
    J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder.
    Atkinson S; Lubaczewski S; Ramaker S; England RD; Wajsbrot DB; Abbas R; Findling RL
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):55-65. PubMed ID: 29185786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
    Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.